Evidence map›Paper›PMID 32833022›Full record

ArticleHuman molecular genetics2020

Genetic determinants of increased body mass index mediate the effect of smoking on increased risk for type 2 diabetes but not coronary artery disease.

Christopher S Thom, Zhuoran Ding, Michael G Levin, Scott M Damrauer, Kyung Min Lee, Julie Lynch, Kyong-Mi Chang, Philip S Tsao, Kelly Cho, Peter W F Wilson and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Human molecular genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 1 country.

Christopher S ThomDivision of Neonatology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Zhuoran DingDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Michael G LevinCorporal Michael J. Crescenz VA Medical Center, Philadelphia, PA 19104, USA.
Scott M DamrauerDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Kyung Min LeeVA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT 84148, USA.
Julie LynchVA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT 84148, USA.
Kyong-Mi ChangCorporal Michael J. Crescenz VA Medical Center, Philadelphia, PA 19104, USA.
Philip S TsaoVA Palo Alto Health Care System, Palo Alto, CA 94304, USA.
Kelly ChoVA Boston Healthcare System, Boston, MA 02130, USA.
Peter W F WilsonAtlanta VA Health Care System, Decatur, GA 30033, USA.
Themistocles L AssimesVA Palo Alto Health Care System, Palo Alto, CA 94304, USA.
Yan V SunAtlanta VA Health Care System, Decatur, GA 30033, USA.
Christopher J O'DonnellVA Boston Healthcare System, Boston, MA 02130, USA.
VA Million Veteran Program
Marijana VujkovicCorporal Michael J. Crescenz VA Medical Center, Philadelphia, PA 19104, USA.
Benjamin F VoightDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Philadelphia VA Medical Center · USTranslational Therapeutics (United States) · USBrigham and Women's Hospital · USEmory University · USVA Palo Alto Health Care System · USChildren's Hospital of Philadelphia · USUniversity of Massachusetts Boston · USUniversity of Pennsylvania · USVA Salt Lake City Healthcare System · US

Funding

T32 Institutional Pediatric ResearchT32HD043021 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI Joseph W. St. Geme · 2002 to 2026
$6.4M
Network-based algorithms for target identification and drug repositioning from genetic associationsR01HG010067 · NHGRI · UNIVERSITY OF PENNSYLVANIA · PI GREENE, CASEY S · 2018 to 2022
$3.2M
Algorithms to identify non-coding mutational burden and disease-relevant pathwaysR01DK101478 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI VOIGHT, BENJAMIN FRANKLIN · 2014 to 2018
$2.9M
Algorithms to identify non-coding mutational burden and disease-relevant pathwaysR56DK101478 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI VOIGHT, BENJAMIN FRANKLIN · 2019 to 2019
$272k
Precision Cardio-Metabolic Phenotyping for Genetic Discovery and Risk PredictionIK2CX001780 · VA · PHILADELPHIA VA MEDICAL CENTER · PI DAMRAUER, SCOTT MICHAEL · 2018 to 2023
–
BLRD VA I01 BX003340BLRD VA I01 BX003362BLRD VA I01 BX004821CSRD VA IK2 CX001780NHGRI NIH HHS R01 HG010067NICHD NIH HHS T32 HD043021NIDDK NIH HHS R01 DK101478NIDDK NIH HHS R56 DK101478
6 · The paper itself

Abstract

Clinical observations have linked tobacco smoking with increased type 2 diabetes risk. Mendelian randomization analysis has recently suggested smoking may be a causal risk factor for type 2 diabetes. However, this association could be mediated by additional risk factors correlated with smoking behavior, which have not been investigated. We hypothesized that body mass index (BMI) could help to explain the association between smoking and diabetes risk. First, we confirmed that genetic determinants of smoking initiation increased risk for type 2 diabetes (OR 1.21, 95% CI: 1.15-1.27, P = 1 × 10-12) and coronary artery disease (CAD; OR 1.21, 95% CI: 1.16-1.26, P = 2 × 10-20). Additionally, 2-fold increased smoking risk was positively associated with increased BMI (~0.8 kg/m2, 95% CI: 0.54-0.98 kg/m2, P = 1.8 × 10-11). Multivariable Mendelian randomization analyses showed that BMI accounted for nearly all the risk smoking exerted on type 2 diabetes (OR 1.06, 95% CI: 1.01-1.11, P = 0.03). In contrast, the independent effect of smoking on increased CAD risk persisted (OR 1.12, 95% CI: 1.08-1.17, P = 3 × 10-8). Causal mediation analyses agreed with these estimates. Furthermore, analysis using individual-level data from the Million Veteran Program independently replicated the association of smoking behavior with CAD (OR 1.24, 95% CI: 1.12-1.37, P = 2 × 10-5), but not type 2 diabetes (OR 0.98, 95% CI: 0.89-1.08, P = 0.69), after controlling for BMI. Our findings support a model whereby genetic determinants of smoking increase type 2 diabetes risk indirectly through their relationship with obesity. Smokers should be advised to stop smoking to limit type 2 diabetes and CAD risk. Therapeutic efforts should consider pathophysiology relating smoking and obesity.

Indexed as

Body Mass IndexGenome-Wide Association StudyPolymorphism, Single NucleotideCoronary Artery DiseaseDiabetes Mellitus, Type 2Genetic Predisposition to DiseaseHumansMendelian Randomization AnalysisObesityRisk FactorsSmoking

Identifiers

PMID32833022
PMCPMC7689293
OpenAlexW3080813012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.